

RESEARCH ARTICLE

Toxic Effects of Fumonisin B1 Mycotoxin on Caco-2 Human Intestinal Cell Line

Garbetta Antonella¹, Debellis Lucantonio² and Minervini Fiorenza¹

¹Institute of Sciences of Food Production, National Research Council of Italy (CNR), Italy ²Department of Biosciences, Biotechnologies and Biopharmaceutics, University of Bari, Italy

ARTICLEINFO

Article history: Received: 05 January 2017 Accepted: 04 September 2017 Published: 15 September 2017

Keywords: Microviscosity; Fumonisin B1; Intestinal cell line; MTT test; Oxidative status

Copyright: © 2017 Fiorenza M et al., Nutri Food Sci J

This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citation this article: Antonella G, Lucantonio D, Fiorenza M. Toxic Effects of Fumonisin B1 Mycotoxin on Caco-2 Human Intestinal Cell Line. Nutri Food Sci J. 2017; 1(1):111.

Correspondence: Minervini Fiorenza,

Institute of Sciences of Food Production, National Research Council of Italy (CNR), Italy; Email: Fiorenza.minervini@ispa.cnr.it

ABSTRACT

The gastrointestinal tract is the main site of exposure to Fumonisin B1 (FB₁), common mycotoxin contaminant of corn and its derivative products. This study, therefore, aims to investigate the effects of such exposure analysing the timeand dose-dependent modifications of some functional parameters induced by FB₁ on the human colon intestinal line (Caco-2). Cell proliferation, oxidative status and changes in membrane microviscosity were assessed using MTT test, malondialdehyde levels related with lipid peroxidation and fluorescence anisotropy, respectively. Short-term exposure of Caco-2 cells to FB₁ induced inhibition of cell proliferation with temporary changes in membrane microviscosity and increased oxidative stress. The observed early FB₁ toxicity was probably due to interactions between the mycotoxin and the cellular membrane, presumably related to amphipathic sphingoid-like structure of mycotoxin.

Abbreviations: FB₁: Fumonisin B₁; MDA: Malondialdehyde; TMA-DPH, N,N,N-Trimethyl-4-(6-phenyl-1,3,5-hexatriene-1-yl) Phenylammonium p-toluenesulfonate.

Introduction

Fumonisin B1 (FB1) is a mycotoxin produced mainly by isolates of Fusarium verticillioides and F. proliferatum and classified by IARC as "possible carcinogenic to humans" [1]. The WHO reported that FB1 was commonly found in corn and its derivative products all over the world: the contamination was found in 77% of samples from Africa, 85% of samples from Latin America, 63% of samples from North America, 53% of samples from Europe and 52% of samples from Asia [2]. Due to the high occurrence of FB1 in corn, although at levels permitted by worldwide regulations, humans are constantly exposed to low levels of FB1, with a higher risk for those countries where corn is the prevalent food; hence, the gastro-intestinal tract could represent the first target of exposure to FB1 that, although not absorbed by the intestine when administered orally, is found to be hazardous to human health, a condition qualified by Shier [3] as the "fumonisin paradox". For its chemical similarity to sphingoid bases, such as sphingosine and sphinganine, the FB1 toxicity is related to the inhibition of ceramide synthase, a key enzyme in de novo sphingolipid biosynthesis and in the sphingolipid salvage pathway.



NUTRITION AND FOOD SCIENCE JOURNAL

The inhibition of ceramide synthase by FB1 induces the increased intracellular sphinganine and sphingosine ratio, normally used as biomarker for the assessment of mycotoxin exposure [4]. Consequent to inhibition of ceramide biosynthesis, oxidative stress and apoptosis induction have been reported as toxicity mechanisms on intestinal cell line [5]. Since, FB1 could modify the biological properties of plasma membrane directly, interfering with membrane configuration, due to its amphipathic sphingoid-like structure [6], and indirectly inducing changes on phospholipid composition [7], the aim of the present study was to investigate these specific effects on human intestine using cell line (Caco-2) as model. Dose- and time-dependent effects induced by exposure to FB1 on cell viability, proliferation, oxidative status and membrane microviscosity were assessed.

Materials and methods

1 Reagents

Dulbecco's Modified Eagle's medium, Dulbecco's Phosphate Buffered Saline (PBS), Trypsin-EDTA Solution, L-glutamine 200 mM, Antibiotic and Antimycotic Solution, Thiazolyl Blue Tetrazolium Bromide (MTT), Trypan Blue Solution, N,N,N-Trimethyl-4-(6-phenyl-1,3,5-hexatriene-1-yl) phenylammonium p-toluenesulfonate (TMA-DPH) were purchased from Sigma Aldrich (Milan, Italy). Non Essential Amino acid Solution was purchased from Euroclone (Milan, Italy). Foetal Bovine Serum (FBS) was purchased from Gibco (Milan, Italy). Fumonisin B₁ standard was purchased from Orsell (Modena, Italy). Lipid Peroxidation (MDA) Assay Kit (BIOVISION) was purchased from Vinci-Biochem (Florence, Italy).

2 Human intestinal cell line

The human colon carcinoma cell line Caco-2 (ECACC, Sigma Aldrich) was grown in 25 cm² flasks at a starting density of 250,000 cells/ml in Dulbecco's Modified Eagle's Medium with 4.5 g/L glucose supplemented with 10% of FBS, 1% of L-Glutamine, 1% Antibiotic and Antimycotic solution, 1% non essential amino acid solution. Density and cell viability were determined using Trypan blue dye and a Bürker counting chamber. The cells used for experimental protocols showed a mean viability of 90%.

SCIENTIFIC LITERATURE

3 Evaluation of toxicity induced by FB1 on intestinal cells

3.1 Preparation of Fumonisin B1 solution

Fumonisin B_1 solution was prepared following the protocol described in Minervini et al [8]. The choice of highest FB₁ concentration (69 μ M) was based on the FB₁ toxicity evaluation found in previous *in vitro* studies [3,9,10].

3.2 Assessment of cell viability and proliferation

To test the influence of FB₁ on cell viability and the proliferation of Caco-2 intestinal cell line, Trypan blue dye exclusion and a colorimetric MTT assay were used, respectively. Caco-2 human colon cell line was seeded at a cell density of 100,000 cells/ml in 96-well plate, exposed at FB₁ concentrations (from 0.5 to 69 μ M) and incubated from 24 to 72 hours. MTT test and viability assay followed the protocols described by Minervini et al [8].

3. 3 Assessment of lipid peroxidation.

Time (from 6 to 24 hours) and dose-dependent effect induced by FB_1 on the lipid peroxidation was assessed using Lipid Peroxidation Assay Kit (Biovision), as reported by Minervini et al [8].

3.4 Fluorescence anisotropy to assess membrane microviscosity after FB1 exposure


Considering previous references on FB₁-dependent modifications to membrane fluidity [7,11] assessed by fluorescence anisotropy, we applied this method in order to assess the microviscosity of intestinal cell line after FB₁ exposure.

Time (from 6 to 24 hours) and dose-dependent experiments, using cationic derivative of diphenylhexatriene, TMA-DPH probe, and calculation of anisotropy values, were performed following the protocol described by Minervini et al [8].

4 Statistical analysis

Statistical analysis was performed using SigmaPlot software v.11 (Systat Software, Inc. SigmaPlot for Windows). Multiple Comparisons Dunn's Method was used to evaluate the significant difference between FB₁ concentrations and control samples. Values of p<0.05 were considered statistically different.

SCIENTIFIC LITERATURE



Results and Discussion

1 Assessment of cell viability and proliferation

Time- and dose-dependent experiments were carried out in order to assess the effect of exposure to FB₁ (24, 48 and 72 hours) on cell viability and proliferation of intestinal Caco-2 cell line. Exposure to FB₁ did not affect cell viability (79% \pm 6 after exposure to 69 µM of FB₁ vs. 92% \pm 9.9 in control sample) after each time incubation tested in the protocol, in agreement with data reported by Caloni et al [9]. Effect of FB₁ on cell proliferation was not marked and did not exceed 30% of inhibition. A significant (p<0.05 vs. control) but doseindependent reduction in cell proliferation was observed after 24 hours exposure at FB₁ concentrations ranging from 4.3 to 69 µM. No influence of FB₁ on cell proliferation was observed after 48 and 72 hours of exposure. Our results are not in agreement with the inhibition of cell proliferation found on Caco-2 cells by Kouadio et al [5] and the discrepancy is probably related to different culture conditions.

2 Assessment of lipid peroxidation

Fumonisin B1 induced time-related redox imbalance on intestinal cell line. An early induction of lipid peroxidation was observed on Caco-2 cell line after 6 hours of incubation with FB1. As reported in Figure 1A, an increase in MDA production, ranging from 0.3 to 0.7 nmol/mg of cellular pellet, was observed. The rise was not related to FB1-concentration. A significant (p<0.05) production of MDA, ranging from 0.6 to 1.2 nmol/mg of cellular pellet, was observed after 12 hours of exposure to FB1 at each concentration tested (Figure 1B). Similar significant (p<0.05) MDA production was observed after 24 hours of exposure to FB1 with an evident dependence in the range from 2.1 to 69 μ M of FB₁ (Figure 1C). These results were in agreement with the strong oxidative stress (assessed as MDA production after 24 hours) reported by Kouadio et al [5], on Caco-2 intestinal and by Ferrante et al [11] on macrophage cell lines, although at different FB1 concentrations.

3 Assessment of membrane microviscosity after FB1 exposure by fluorescence anisotropy

Fumonisin B_1 induced a significant (p<0.05) early in Caco-2 cell membrane increase microviscosity (recorded as 10% reduction in fluorescence polarization) after 6 hours of exposure at all tested concentrations (from 0.5 to 69 µM). After increased exposure times (12 and 24 hours), FB1 did not induce any change in membrane microviscosity. Similar results were found by Ferrante et al [11] on macrophage cell line, but with higher FB1 levels (up to 10 µM) and longer exposure time (24 hours).

In our previous study [8] performed on HT-29 human intestinal cell line, different time-dependent toxic effects of FB₁ was found in respect with the present data on Caco-2 cells. In fact, HT-29 intestinal cell line exposed to FB₁ showed late inhibition of cell proliferation, a rise of the oxidative status together with an increase of membrane fluidity. These effects are probably related

SCIENTIFIC LITERATURE

NUTRITION AND FOOD SCIENCE JOURNAL

to FB1 intracellular absorption, as also demonstrated by our microscopic confocal observations [8] and consequent inhibition of the sphingolipid metabolism, as reported by Schmeltz et al [12]. By contrast, the earlier toxic effect induced by FB1 on Caco-2 cells, reflected by the increase in microviscosity and induction of lipid peroxidation, could be consequent to the interaction between FB1 and the cell membrane. As reported by several Authors [6,7], the interaction with FB1 leads to modifications in the lipid composition and functionality of the cell membrane. Yin et al [13] indicated that the interaction between of the FB1 and lipid bilayers has multiple effects, such as modification of the membrane structure and influence on the cell membrane's oxygen transport properties. The results reported in this study confirmed the existence of different toxic mechanisms cell/organ type-related induced by FB_1 [7,14].

Conclusion

The toxic mechanisms induced by FB₁ were different in relation to cell/organ type. On Caco-2 human intestinal cell line, in our conditions, lipid peroxidation and modification of membrane microviscosity were the early toxic mechanisms induced by FB₁ probably related to the direct interaction between mycotoxin and cellular membrane. Such toxic effects were observed at FB₁ concentrations (up to 0.5 μ M corresponding to 0.4 ppm) much higher than the mean FB₁ food levels reported by SCOOP [15] in Europe (from 31.5 to 74.2 ppb).

Acknowledgement

This work was supported in part by EC KBBE-2007-222690-2 MYCORED.

References

1. WHO-IARC,1993. IARC monographs on the evaluation of carcinogenic risk to humans. - Some naturally occurring substances: food items and constituents, heterocyclic aromatic amines and mycotoxins. Lyon IARC 56, 445-466.

 International Programme on Chemical Safety (IPCS). Environmental Health Criteria 219. 2000.
Fumonisin B1. (Eds) Marasas, W.F.O., Miller, J.D., Riley, R.T., Visconti, A., World Health Organization. Shier WT. (2000). The fumonisin paradox: A review of research on oral bioavailability of Fumonisin B1, a mycotoxin produced by Fusarium moniliforme. J. Toxicol. Toxin. Rev. 19: 161-187.

4. Soriano JM, González L, Catalá Al. (2005). Mechanism of action of sphingolipids and their metabolites in the toxicity of Fumonisin B1. Prog Lipid Res. 44(6):345-356.

5. Kouadio JH, Mobio TA, Baudrimont I, Moukha S, Dano SD, Creppy EE. (2005). Comparative study of cytotoxicity and oxidative stress induced by deoxynivalenol, zearalenone or fumonisin B1 in human intestinal cell line Caco-2. Toxicology 15;213(1-2):56-65.

6. Yin JJ, Smith MJ, Eppley RM, Troy AL, Page SW, Sphon JA. (1996) Effects of fumonisin B1 and (hydrolyzed) fumonisin backbone AP1 on membranes: a spin-label study. Arch Biochem Biophys. 1;335(1):13-22.

 Theumer MG, Clop EM, Rubinstein HR, Perillo MA. (2008). The lipid-mediated hypothesis of fumonisin B1 toxicodynamics tested in model membranes. Colloids Surf B Biointerfaces. 15;64(1):22-33.

8. Minervini F, Garbetta A, D'Antuono I, Cardinali A, Martino NA, Debellis L, Visconti A. (2014). Toxic mechanisms induced by fumonisin B1 mycotoxin on human intestinal cell line. Arch Environ Contam Toxicol. 67(1):115-23.

9. Caloni F, Spotti M, Pompa G, Zucco F, Stammati A, De Angelis I. (2002). Evaluation of Fumonisin B1 and its metabolites absorption and toxicity on intestinal cells line Caco-2. Toxicon. 40(8):1181-188.

10. Bouhet S, Hourcade E, Loiseau N, Fikry A, Martinez S, Roselli M, Galtier P, Mengheri E, Oswald IP. (2004). The mycotoxin fumonisin B1 alters the proliferation and the barrier function of porcine intestinal epithelial cells. Toxicol Sci. 77(1):165-71.

11. Ferrante MC, Meli R, Mattace Raso G, Esposito E, Severino L, Di Carlo G, Lucisano A. (2002) Effect of fumonisin B1 on structure and function of macrophage plasma membrane. Toxicol Lett. 28;129(3):181-7.

Schmelz EM, Dombrink-Kurtzman MA, Roberts
PC, Kozutsumi Y, Kawasaki T, Merrill AH Jr. (1998).
Induction of apoptosis by fumonisin B1 in HT29 cells is

NUTRITION AND FOOD SCIENCE JOURNAL

SCIENTIFIC LITERATURE

mediated by the accumulation of endogenous free sphingoid bases. Toxicol Appl Pharmacol. 148(2):252-60.

13. Yin JJ1, Smith MJ, Eppley RM, Page SW, Sphon JA. (1998). Effects of fumonisin B1 on lipid peroxidation in membranes. Biochim Biophys Acta. 22;1371(1):134-42.

14. Riley RT, Enongene E, Voss KA, Norred WP, Meredith FI, Sharma RP, Spitsbergen J, Williams DE, Carlson DB, Merrill AH Jr. (2001). Sphingolipid perturbations as mechanisms for fumonisin carcinogenesis. Environ Health Perspect. 109 Suppl 2:301-8.

15. SCOOP (2003). Collection of occurrence data of Fusarium toxins in food and assessment of dietary intake by the population of EU Member States. Subtask II Fumonisins (Eds.) Brera C, Miraglia M. 485-576